Agilent Technologies to provide Paradigm Genetics with microarrays for toxicogenomics research

15-Nov-2002

Agilent Technologies Inc. announced a multi-year agreement to provide Paradigm genetics Inc. with 60-mer oligonucleotide-based microarrays for their toxicogenomics research, the results of which are planned to be compiled in a public database that will be available to the scientific community.

This agreement comes as a direct result of Paradigm's five-year, $23.8 million contract with the National Institute of Environmental Health Sciences (NIEHS) to use gene expression profiling methods to measure the physiological effects of a toxicant, drug or pesticide on an organism. As outlined in their proposal to the NIEHS, Paradigm will use a gene expression platform for its research that is based on instrumentation, reagent chemistries, informatics and microarrays manufactured by Agilent.

Researchers today have little information about what happens at the genetic level between the time that an organism is exposed to a toxic element and the time when an outcome, such as a disease, appears. Paradigm's project seeks to identify similarities and differences between responses in order to more fully understand this process. Eventually, the genetic profiles of organism responses to toxicants will be collected into a toxicogenomics database that will be publicly available to the scientific community for their research.

https://www.chemeurope.com/en/news/15789/agilent-technologies-to-provide-paradigm-genetics-with-microarrays-for-toxicogenomics-research.html